Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial

Summary

Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the progression free survival and safety of irinotecan plus S1 versus S1 alone in the patients with previously treated advanced esophageal cancer

Timeline

Start

2014-12

Primary completion

2016-12

Completion

2017-06

Outcome

Met primary endpoint

paper the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group PMID 30940189 ↗

paper P = 0.006 PMID 30940189 ↗

Publications

• Huang J, Xu B, Liu Y, Huang J, Lu P, Ba Y, Wu L, Bai Y, Zhang S, Feng J, Cheng Y, Li J, Wen L, Yuan X, Ma C, Hu C, Fan Q, Wang X. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer Commun (Lond). 2019 Apr 2;39(1):16. doi: 10.1186/s40880-019-0359-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	160 mg/m2	Intravenous
Subject	S-1	Small molecule	80 mg	Oral
Subject	S-1	Small molecule	120 mg	Oral

Indications